OR WAIT null SECS
Check out the latest features and columns!
These five brands prove that pharma marketers can pull it together with compelling stories, and meaningful patient impact, even during a pandemic.
October's Executive Profile features Imvax CEO John Furey
How can clinical trials be designed to best study therapies for treating long COVID?
Pharm Exec’s latest listing of the top global biopharma sales producers captures the critical business and public health balancing act that was required in the Year of COVID.
Read the profiles of 13 diverse leaders vital to the future of the biopharma industry.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Highlighted Videos
October 28, 2021
FDA is seeking to address the added complexities for incorporating real-world data and real-world evidence into submissions to the agency, while addressing concerns about its relevance and reliability.
Christian Wieszner, CSL Behring UK’s new General Manager, talks about his role and his vision for the company’s UK operation going forward.
October 26, 2021
The increased interest from HCPs to implement more virtual communication with sales representatives highlights the importance of the hybrid sales model. Competition is fierce - how does one hybrid team distinguish itself and stand out from the crowd to find success for the company?
The release from the partnership addresses a key issue that brand marketers and their agencies of record face in healthcare: how to prioritize audience outreach while properly navigating the privacy regulations.
October 25, 2021
Mark Materacky talks about Novo Nordisk and Queen Latifah’s “It's Bigger Than Me” campaign to change the way the world looks at and discusses obesity.
October 22, 2021
Lowenthal, an award-winning creative, will bring his expertise to help build on the Human Dynamics approach of MicroMass, which aligns brands with the evolving needs of patients.
Solution leverages AI and natural language processing to accelerate and improve the review of materials used to market pharmaceutical and medical device products.
Having proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.
October 21, 2021
FDA is expanding its Emerging Technology Program (ETP) and providing more support for new drug applications (NDAs) that present advanced manufacturing technologies, but the agency and industry face key challenges in advancing these initiatives.
Carlyle and co-investors including Amgen Ventures, Merck Global Health Innovation Fund, Pfizer Ventures, and Population Health Partners to acquire majority stake in Saama Technologies.
